JP7590713B1 - がん治療用組み合わせ医薬 - Google Patents

がん治療用組み合わせ医薬 Download PDF

Info

Publication number
JP7590713B1
JP7590713B1 JP2024529314A JP2024529314A JP7590713B1 JP 7590713 B1 JP7590713 B1 JP 7590713B1 JP 2024529314 A JP2024529314 A JP 2024529314A JP 2024529314 A JP2024529314 A JP 2024529314A JP 7590713 B1 JP7590713 B1 JP 7590713B1
Authority
JP
Japan
Prior art keywords
culture
inhibitor
cancer
cbm588
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024529314A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024241468A5 (https=
JPWO2024241468A1 (https=
Inventor
範克 三吉
彩 伊藤
彩香 東城
志達 高橋
健太郎 岡
篤史 林
逸美 工藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Miyarisan Pharmaceutical Co Ltd
Osaka Prefectural Hospital Organization
Original Assignee
Miyarisan Pharmaceutical Co Ltd
Osaka Prefectural Hospital Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miyarisan Pharmaceutical Co Ltd, Osaka Prefectural Hospital Organization filed Critical Miyarisan Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP7590713B1 publication Critical patent/JP7590713B1/ja
Publication of JPWO2024241468A1 publication Critical patent/JPWO2024241468A1/ja
Publication of JPWO2024241468A5 publication Critical patent/JPWO2024241468A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024529314A 2023-05-23 2023-05-23 がん治療用組み合わせ医薬 Active JP7590713B1 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2023/019078 WO2024241468A1 (ja) 2023-05-23 2023-05-23 がん治療用組み合わせ医薬

Publications (3)

Publication Number Publication Date
JP7590713B1 true JP7590713B1 (ja) 2024-11-27
JPWO2024241468A1 JPWO2024241468A1 (https=) 2024-11-28
JPWO2024241468A5 JPWO2024241468A5 (https=) 2025-04-30

Family

ID=93588015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529314A Active JP7590713B1 (ja) 2023-05-23 2023-05-23 がん治療用組み合わせ医薬

Country Status (4)

Country Link
EP (1) EP4717274A1 (https=)
JP (1) JP7590713B1 (https=)
CN (1) CN121152637A (https=)
WO (1) WO2024241468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08252088A (ja) * 1995-03-17 1996-10-01 Nippo Kagaku Kk クロストリジウム属細菌の培養方法
JP2009269836A (ja) * 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
WO2021020554A1 (ja) * 2019-07-31 2021-02-04 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ－３遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法
WO2021216618A1 (en) * 2020-04-21 2021-10-28 City Of Hope Compositions and methods comprising clostridium butyricum for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08252088A (ja) * 1995-03-17 1996-10-01 Nippo Kagaku Kk クロストリジウム属細菌の培養方法
JP2009269836A (ja) * 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
WO2021020554A1 (ja) * 2019-07-31 2021-02-04 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ－３遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法
WO2021216618A1 (en) * 2020-04-21 2021-10-28 City Of Hope Compositions and methods comprising clostridium butyricum for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DE ALMEIDA LEITE, Rodrigo Moises et al.，Regorafenib - Five Years in Review，European Oncology & Haematology，2020年，Vol. 16, no. 1，p. 24-28
DE ALMEIDA LEITE, RODRIGO MOISES ET AL.: "Regorafenib - Five Years in Review", EUROPEAN ONCOLOGY & HAEMATOLOGY, vol. 16, no. 1, JPN6023032382, 2020, pages 24 - 28, ISSN: 0005362973 *
MEZA, L.A. et al.，A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination wit，Journal of Clinical Oncology，2022年06月02日，vol. 40, issue 16, suppl.，TPS4606，特に「background」欄,「method」欄
MEZA, L.A. ET AL.: "A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination wit", JOURNAL OF CLINICAL ONCOLOGY, vol. vol. 40, issue 16, suppl., JPN6023032380, 2 June 2022 (2022-06-02), pages 4606, ISSN: 0005448780 *

Also Published As

Publication number Publication date
JPWO2024241468A1 (https=) 2024-11-28
EP4717274A1 (en) 2026-04-01
WO2024241468A1 (ja) 2024-11-28
CN121152637A (zh) 2025-12-16

Similar Documents

Publication Publication Date Title
US10987387B2 (en) Compositions comprising bacterial strain
US11058732B2 (en) Compositions comprising bacterial strains
EP4316499A1 (en) Lactobacillus plantarum gb104 strain and composition comprising same for prevention or treatment of cancer
EP3422867B1 (en) Direct-fed microbials
WO2014185516A1 (ja) 反芻動物の乳房炎の予防または治療剤
US20230048366A1 (en) Combination therapy for treating or preventing cancer
JP2023540711A (ja) 抗癌活性を有するラクトバチルス・プランタルム微生物、それを含む組成物、及びそれを利用した癌の予防方法または治療方法
JP7590713B1 (ja) がん治療用組み合わせ医薬
CN119868398A (zh) 用于促进免疫检查点抑制疗法的组合物
JP2023539910A (ja) 免疫チェックポイント阻害剤の増強剤の調製における細菌の使用
JP7072151B2 (ja) 腸内菌叢改善剤
JP7725011B1 (ja) Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物
WO2023072968A1 (en) Compositions comprising bacterial strains
WO2023041203A1 (en) Compositions comprising bacterial strains
HK1258786A1 (en) Compositions comprising bacterial strains
HK1254166B (zh) 包含细菌菌株的组合物
OA18794A (en) Compositions comprising bacterial strains.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240516

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241105

R150 Certificate of patent or registration of utility model

Ref document number: 7590713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150